Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xtandi
Pharma
Pfizer eyes earlier Talzenna use after ph. 3 prostate cancer win
If approved, Talzenna would be the first PARP inhibitor to enter the HRR-mutant metastatic hormone-sensitive prostate cancer setting.
Angus Liu
Mar 19, 2026 6:45am
Astellas, Takeda, Chugai and more—Fierce Pharma Asia
Jan 23, 2026 9:05am
Astellas CEO resists 'rescue BD' as Xtandi patent cliff nears
Jan 15, 2026 10:42am
Lilly-Innovent, Dizal, bispecific ADC—Fierce Pharma Asia
Jul 10, 2025 5:20pm
Pfizer, Astellas' Xtandi combo extends life in early prostate cancer
Jul 10, 2025 11:52am
FDA approves use of Bayer's Nubeqa in all patients with mCSPC
Jun 4, 2025 11:38am
